You are here: Industry Insights > diabetes drugs

News List

Turbulent Patterns of DPP-4 Inhibitor Hypoglycemics: First Generic of Linagliptin Approved and a New Manufacturer Approved to Market Vildagliptin PharmaSources/Miling
July 22, 2020
Guangdong HEC Pharmaceutical’s Class 4 generic drug: Linagliptin Tablets and Nanjing Sanhome Pharmaceutical’s Class 4 generic drug.
Diabetes drugs cost NHS more than £1bn a year pharmaphorum
December 04, 2018
Diabetes prescriptions are costing the NHS in England more than £1 billion a year, driven by an increase in the number of patients rather than rising drug costs.
Access to Diabetes Drugs Improved Under Affordable Care Act: Study drugs
August 07, 2018
People with diabetes face a host of expenses related to their disease, but some relief may now be available in states that expanded Medicaid eligibility as part of the Affordable Care Act.
A Glimpse of the Situation of SGLT-2 Inhibitors, the Up-rising Star of Oral Hypoglycemic Drugs, in China Xiaoyaowan
June 28, 2018
The market size of the global hypoglycemic drugs exceeded USD 40 billion in 2017, which became the second largest drug market next only to the oncology drug market.
Diabetes drugs market will be worth US$58.4 billion by the end of 2025 pharmaasia
December 21, 2017
Among the factors expected to boost the diabetes drugs market are sedentary lifestyles, increasing disposable incomes and increasing geriatric populations.
Diabetes drug could be key to treating aggressive breast cancer, research suggests pharmafile
March 09, 2017
Researchers from the Zhejiang University School of Medicine have identified that the function of...
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk europeanpharmaceuticalreview
January 06, 2017
The US Food and Drug Administration (FDA) approved supplemental new drug applications for three type 2 diabetes medicines within the empagliflozin family to include data from the empa-red outcome trial.